Incruse Ellipta (Umeclidinium Bromide)

Incruse Ellipta, a long‑acting muscarinic antagonist, is used in the management of chronic obstructive pulmonary disease (COPD).

• COPD: Improves lung function and reduces the frequency of exacerbations when used regularly as maintenance therapy.
• Chronic bronchitis: Provides bronchodilation to relieve persistent cough and sputum production associated with the bronchitic component of COPD.
• Emphysema: Helps maintain airway patency and exercise tolerance in patients with emphysematous changes.

• Umeclidinium bromide selectively antagonizes muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine‑mediated bronchoconstriction. Its high affinity and slow dissociation from the receptor produce prolonged bronchodilation, thereby improving airflow and reducing symptoms in chronic obstructive pulmonary disease.

Common Side Effects

• Dry mouth: Reduced salivary secretion leading to a sensation of dryness.
• Cough: Transient irritation of the throat during inhalation.
• Throat irritation: Discomfort or soreness in the throat after use.
• Headache: Mild to moderate headache reported by some users.

Serious or Rare Side Effects

• Paradoxical bronchospasm: Sudden worsening of breathing requiring immediate medical attention.
• Allergic reactions: Rash, pruritus, or angioedema indicating hypersensitivity.
• Urinary retention: Difficulty emptying the bladder, especially in patients with prostate enlargement.

Before initiating therapy, consider the following precautions:

• Assess renal function: Monitor patients with severe impairment, although dose adjustment is not routinely required.
• Avoid use in patients with known hypersensitivity to umeclidinium or any excipients in the inhaler.
• Use with caution in patients with narrow‑angle glaucoma, as anticholinergic effects may increase intra‑ocular pressure.
• Monitor for urinary retention in individuals with prostate enlargement or bladder outlet obstruction.
• Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Umeclidinium may interact with other medicines; review the following categories.

Major Interactions (Avoid)

• Anticholinergic drugs: Additive anticholinergic effects can increase dry mouth and urinary retention.
• Strong CYP3A4 inhibitors: May raise systemic exposure of umeclidinium, potentially enhancing adverse effects.
• Beta‑agonists: Concurrent high‑dose use may lead to excessive bronchodilation and tachycardia.

Moderate Interactions (Monitor Closely)

• Other inhaled bronchodilators: Combined use may require clinical monitoring for efficacy and side‑effects.
• Diuretics: May exacerbate dehydration caused by dry mouth.
• Antihistamines: Combined anticholinergic load may increase risk of cognitive effects in susceptible patients.